Division of Nephrology, Montreal Children's Hospital, McGill University Health Centre, Montreal, Canada.
Clin J Am Soc Nephrol. 2012 Nov;7(11):1761-9. doi: 10.2215/CJN.12751211. Epub 2012 Aug 23.
This study determined if preoperative and postoperative urine albumin/creatinine ratios (ACRs) predict postoperative AKI in children undergoing cardiac surgery (CS).
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a three-center, prospective study (2007-2009) of 294 children undergoing CS (n=145 aged <2 years). Urine ACR was measured preoperatively and 0-6 hours after intensive care unit arrival. AKI outcomes were based on the Acute Kidney Injury Network serum creatinine (SCr) criteria (stage 1 AKI, ≥50% or 0.3 mg/dl SCr rise from baseline; and stage 2 or worse AKI, ≥SCr doubling or dialysis). AKI was predicted using preoperative and postoperative ACRs and postoperative ACR performance was compared with other AKI biomarkers.
Preoperative ACR did not predict AKI in younger or older children. In children aged <2 years, first postoperative ACR ≥908 mg/g (103 mg/mmol) predicted stage 2 AKI development (adjusted relative risk, 3.4; 95% confidence interval, 1.2-9.4). In children aged ≥2 years, postoperative ACR ≥169 mg/g (19.1 mg/mmol) predicted stage 1 AKI (adjusted relative risk, 2.1; 95% confidence interval, 1.1-4.1). In children aged ≥2 years, first postoperative ACR improved AKI prediction from other biomarker and clinical prediction models, estimated by net reclassification improvement (P≤0.03), but only when serum cystatin C was also included in the model.
Postoperative ACR is a readily available early diagnostic test for AKI after pediatric CS that performs similarly to other AKI biomarkers; however, its use is enhanced in children aged ≥2 years and in combination with serum cystatin C.
本研究旨在探讨心脏手术(CS)患儿围手术期尿白蛋白/肌酐比值(ACR)能否预测术后急性肾损伤(AKI)。
设计、地点、参与者和测量方法:这是一项在三个中心进行的前瞻性研究(2007-2009 年),共纳入 294 名接受 CS 的儿童(n=145 名年龄<2 岁)。术前和入住重症监护病房后 0-6 小时测量尿 ACR。AKI 结局基于急性肾损伤网络血清肌酐(SCr)标准(AKI 1 期:基线时 SCr 升高≥50%或 0.3mg/dl;AKI 2 期或更差:SCr 倍增或透析)。使用术前和术后 ACR 预测 AKI,比较术后 ACR 与其他 AKI 生物标志物的性能。
术前 ACR 不能预测年龄较小或较大的儿童 AKI。年龄<2 岁的患儿中,首次术后 ACR≥908mg/g(103mg/mmol)预测 AKI 2 期的发生(校正相对风险,3.4;95%置信区间,1.2-9.4)。年龄≥2 岁的患儿中,术后 ACR≥169mg/g(19.1mg/mmol)预测 AKI 1 期(校正相对风险,2.1;95%置信区间,1.1-4.1)。年龄≥2 岁的患儿中,首次术后 ACR 改善了其他生物标志物和临床预测模型对 AKI 的预测,通过净重新分类改善(P≤0.03)来评估,但只有当模型中还包括血清胱抑素 C 时才会改善。
术后 ACR 是小儿 CS 后 AKI 的一种易于获得的早期诊断试验,与其他 AKI 生物标志物性能相当;然而,在年龄≥2 岁的患儿和与血清胱抑素 C 联合使用时,其作用得到增强。